bilaterals.org logo
bilaterals.org logo

health


Slovakia payment to Dutch company overturned
Slovakia will no longer have to compensate Achmea B.V., the shareholder of Union ZP health insurer, for €22 million in damage.
Case studies demonstrate EU member state protections threatened by CETA
Regulating in the public interest at risk if Member States ratify Canada-EU trade deal
Theresa May stokes fears NHS ’for sale’ in post-Brexit US trade deal after refusing to rule it out of Trump talks
No-one knows what US will set as ’their requirements for that free trade agreement’, Prime Minister tells MPs.
NAFTA will undermine health unless Canada resists monopolies on medicines
Time and again, Canadians reaffirm their belief in the basic principle of equitable access to health care for all. But the spirit of this very Canadian principle remains in peril as NAFTA negotiations forge ahead.
CSOs challenge PH trade negotiators: Take Philippines out of RCEP!
Philippine civil society groups and social movements stand together to oppose RCEP
Philip Morris: Tobacco giant ordered to compensate Australia
Tobacco giant Philip Morris has been ordered to pay the Australian government millions of dollars after unsuccessfully suing the nation over its world-first plain-packaging laws.
Did free trade with U.S. undermine Canada’s public health?
NAFTA blamed for tripling Canadians’ consumption of high-fructose sweeteners.
Ten principles for trade
The current global trade and investment regime imposes high social and environmental costs on people and planet.
Avoid changing TPP-related laws that damage the health of Malaysians
The Consumers’ Association of Penang calls on the Malaysian government not to make changes to the law relating to intellectual property rights to comply with the Trans-Pacific Partnership Agreement.
TRIPS flexibilities under threat from investment disputes: a closer look at Canada’s “win” against Eli Lilly
Although Canada won in a unanimous decision, the ruling does not, however, guarantee domestic discretion going forward, contrary to the suggestion of some.
Trading with Trump – What we can expect from a UK-US trade deal
A new briefing has outlined the likely elements of a UK-US trade deal and argues that it would contain more extreme forms of all the controversial elements of the deal that was being negotiated between the EU and the USA.
Corporate sovereignty used to bully Ukraine, Colombia and Italy for protecting public health and the environment
ISDS is an attempt to remove the risk of investment from companies, and place it squarely on the public’s shoulders, without any quid pro quo.
Pharmaceutical giant threatens to drag Government before corporate tribunal
Novartis battle against Colombian Government highlights the threats to public health posed by the outrageous investor-state dispute settlement regime and bad “trade” deals.
Eli Lilly loses quixotic quest to get Canada to pay $500 million for rejecting its bad patents
Just the fact that the Canadian government had to go through this massive and expensive process for many years just for rejecting two bad patents should show why ISDS provisions are such a problem.
Canada scores ISDS victory over Eli Lilly
Canada has prevailed over pharmaceutical giant Eli Lilly in a long-running investor-state dispute the drug company filed under NAFTA’s investment chapter.
Govt costs for tobacco case still secret
Taxpayers are still in the dark about how much of their money has been spent on fighting tobacco giant Philip Morris over plain packaging laws.
Trade deal ups risks in Chinese firm’s takeover of seniors’ care giant
FIPA means province could be blocked from improving care standards for residents.
Trade deals can have adverse impact on access to generic medicines
Interview with Dr Peter Ghys, interim director, strategic information and evaluation, UNAIDS
Don’t cry over dead trade agreements
If we can manage our own economies well, new trade pacts will become largely redundant.
MSF press release: RCEP trade deal negotiators must reject terms that would harm access to medicines
International medical humanitarian organisation Médecins Sans Frontières (MSF), along with other health groups, reiterated concerns about harmful intellectual property provisions in the proposed agreement that would increase market monopolies for pharmaceutical corporations and delay or block access to affordable generic medicines.